EIF1AD Antibody, Biotin conjugated
-
中文名稱：EIF1AD兔多克隆抗體, Biotin偶聯(lián)
-
貨號(hào)：CSB-PA850842LD01HU
-
規(guī)格：￥880
-
其他：
產(chǎn)品詳情
-
產(chǎn)品名稱：Rabbit anti-Homo sapiens (Human) EIF1AD Polyclonal antibody
-
Uniprot No.：
-
基因名：EIF1AD
-
別名：EIF1ADProbable RNA-binding protein EIF1AD antibody; Eukaryotic translation initiation factor 1A domain-containing protein antibody; Haponin antibody
-
宿主：Rabbit
-
反應(yīng)種屬：Human
-
免疫原：Recombinant Human Probable RNA-binding protein EIF1AD protein (1-165AA)
-
免疫原種屬：Homo sapiens (Human)
-
標(biāo)記方式：Biotin
-
克隆類型：Polyclonal
-
抗體亞型：IgG
-
純化方式：>95%, Protein G purified
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 -
產(chǎn)品提供形式：Liquid
-
應(yīng)用范圍：ELISA
-
Protocols：
-
儲(chǔ)存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情
-
功能：Plays a role into cellular response to oxidative stress. Decreases cell proliferation.
-
基因功能參考文獻(xiàn)：
- Novel protein haponin regulates cellular response to oxidative stress. PMID: 22095125
-
亞細(xì)胞定位：Nucleus.
-
蛋白家族：EIF1AD family
-
組織特異性：Expressed in the glioblastoma cell line U-87MG, the embryonic kidney cell line HEK293, the pancreatic carcinoma cell line PANC-1, the breast carcinoma cell line MCF-7, the lung cancer cell line NCI-H460, and the chronic myelogenous leukemia cell line K-56
-
數(shù)據(jù)庫(kù)鏈接：
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
